Global private equity and venture capital news and research

Posts Tagged ‘Abingworth’

21 January 2016

Abingworth closes life sciences co-development fund above target on $105m

particles-1038688_1920 Life sciences and healthcare investor Abingworth has closed its eleventh life sciences fund on $105m, exceeding the target of $100m.

23 December 2015

Altitude Life Science leads $40m Series B round in eFFECTOR Therapeutics

bacteria-811861_1920 Venture capital investor Altitude Life Science Ventures has led a $40m financing round for San Diego-based biopharmaceutical company eFFECTOR Therapeutics.

3 December 2015

SV Life Sciences among consortium backing £19m Kesios Therapeutics Series A

microscope-275984_1920 SV Life Sciences and Imperial Innovations were among a syndicate of investors in a £19m Series A financing round for cancer treatment business Kesios Therapeutics.

24 July 2015

Abingworth leads $22m Series A in vaccine company SutroVax

injection_lrg London-based venture capital Abingworth has led a $22m Series A financing round in biopharmaceutical vaccine company SutroVax.

13 January 2015

Lightspeed leads $33m round in clinical diagnostic lab Personalis

biotech lab clinic research Lightspeed Venture Partners has led a $33m Series C financing round in genomics-based clinical diagnostic laboratory Personalis.

19 May 2014

US biopharma Proteon Therapeutics raises $45m Series D

US biopharmaceutical company Proteon Therapeutics has closed a $45m of Series D equity financing, including a $25m tranche to fully fund the first Phase 3 clinical study of its lead product.

28 February 2014

Abingworth raises £225m for tenth life sciences fund

Life sciences and healthcare investor Abingworth has held the final closing of its tenth fund, exceeding its £200m target and raising £225m.

10 October 2013

Abingworth raises more than £200m for latest fund

life science test tube_sq UK-based venture capital firm Abingworth has raised more than $200m for its sixth fund, AltAssets has learned.

8 October 2013

Personalis raises $22m in Abingworth-led Series B

Menlo Park-based startup Personalis, which provides medical exome and genome sequencing and interpretation services, has received $22m in Series B capital.

15 May 2013

Apple Tree and Novartis back Tokai’s $35m Series E

pharmaceutical 12_sq Cancer-focused biotech firm Tokai Pharmaceuticals has wrapped up a $35m Series E round, which was supported by existing investors Apple Tree Partners and Novartis Venture Funds.

Page 1 of 212

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016